Cargando…

Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library

SARS-CoV-2, the etiological agent of the COVID-19 pandemic, is a member of the Coronaviridae family. It is an enveloped virus with ion channels in its membrane, the most characterized of which is the E protein. Therefore, in an attempt to identify blockers of the E channel, we screened a library of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomar, Prabhat Pratap Singh, Krugliak, Miriam, Arkin, Isaiah T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308726/ https://www.ncbi.nlm.nih.gov/pubmed/34201587 http://dx.doi.org/10.3390/ph14070604

Ejemplares similares

Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing
por: Tomar, Prabhat Pratap Singh, et al.
Publicado: (2021)

Zika M—A Potential Viroporin: Mutational Study and Drug Repurposing
por: Tomar, Prabhat Pratap Singh, et al.
Publicado: (2022)

SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine
por: Singh Tomar, Prabhat Pratap, et al.
Publicado: (2020)

Potential Viroporin Candidates From Pathogenic Viruses Using Bacteria-Based Bioassays
por: Tomar, Prabhat Pratap Singh, et al.
Publicado: (2019)

Bacteria-Based Analysis of HIV-1 Vpu Channel Activity
por: Taube, Robert, et al.
Publicado: (2014)

Viroporins of Mpox Virus
por: Basu, Kingshuk, et al.
Publicado: (2023)

Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2
por: Singh, Anamika, et al.
Publicado: (2022)

Repurposing calcium channel blockers as antiviral drugs
por: Jayaseelan, Vijayashree Priyadharsini, et al.
Publicado: (2020)

Promiscuous Binding in a Selective Protein: The Bacterial Na(+)/H(+) Antiporter
por: Alhadeff, Raphael, et al.
Publicado: (2011)

Searching for Blockers of Dengue and West Nile Virus Viroporins
por: Lahiri, Hiya, et al.
Publicado: (2022)

Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach
por: Choudhary, Shweta, et al.
Publicado: (2020)

The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19
por: Ahmad, Iqrar, et al.
Publicado: (2021)

Identification of SARS-CoV-2 inhibitors through phylogenetics and drug repurposing
por: Mishra, Anamika, et al.
Publicado: (2022)

Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies
por: Han, Namshik, et al.
Publicado: (2021)

Applying polypharmacology approach for drug repurposing for SARS-CoV2
por: Jamir, Esther, et al.
Publicado: (2022)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021)

Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023)

The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis
por: Janes, Jeff, et al.
Publicado: (2018)

An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors
por: Trezza, Alfonso, et al.
Publicado: (2020)

Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets
por: Yu, Pei-Chen, et al.
Publicado: (2022)

Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors
por: Chiou, Wei-Chung, et al.
Publicado: (2021)

A Highly Unusual Palindromic Transmembrane Helical Hairpin Formed by SARS Coronavirus E Protein
por: Arbely, Eyal, et al.
Publicado: (2004)

Molecular targets and system biology approaches for drug repurposing against SARS-CoV-2
por: Singh, Rahul Kunwar, et al.
Publicado: (2020)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Tackling SARS-CoV-2: proposed targets and repurposed drugs
por: Joshi, Siddhi, et al.
Publicado: (2020)

Anti-HIV drug repurposing against SARS-CoV-2
por: Sang, Peng, et al.
Publicado: (2020)

Drug repurposing for SARS-CoV-2 (COVID-19) treatment
por: Mtewa, Andrew G., et al.
Publicado: (2022)

Improved and optimized drug repurposing for the SARS-CoV-2 pandemic
por: Cohen, Sarel, et al.
Publicado: (2023)

Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
por: Tummino, Tia A., et al.
Publicado: (2021)

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing
por: Tristán-Flores, Fabiola E, et al.
Publicado: (2021)

Identification of M(pro) inhibitors of SARS-CoV-2 using structure based computational drug repurposing
por: Nath, Virendra, et al.
Publicado: (2021)

Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro
por: Alaofi, Ahmed L., et al.
Publicado: (2022)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries
por: David, Alon Ben, et al.
Publicado: (2021)

Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening
por: Sanachai, Kamonpan, et al.
Publicado: (2022)

Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing
por: Glebov, Oleg O.
Publicado: (2020)

Computational guided approach for drug repurposing against SARS-CoV-2
por: Anand, Jigisha, et al.
Publicado: (2021)

Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
por: Ahsan, Tamim, et al.
Publicado: (2021)

Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing
por: Kern, Charlotte, et al.
Publicado: (2021)

Drug repurposing against SARS-CoV-2 using computational approaches
por: Kumar, Sumit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6o9c0nafkeopvmibolt8q8c0b0